GSK plc plans to invest $30 billion across the U.S. in research and development and supply chain infrastructure over the next five years. This includes a new $1.2 billion investment in advanced manufacturing facilities and AI and advanced digital technologies, to deliver next-generation biopharma factories and labs in the U.S.   The $1.2 billion investment includes: Construction of an additional new biologics flex factory at Upper Merion, PA to deliver potential best-in-class new medicines...